{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:37:31Z","timestamp":1761489451814},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1847,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1093\/annonc\/mdu392","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T04:37:22Z","timestamp":1410410242000},"page":"2191-2196","source":"Crossref","is-referenced-by-count":10,"title":["A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"F.","family":"Selle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Favier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lesoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu392_bb0010","unstructured":"European International Agency for Research on Cancer. Cancer Fact Sheet, Ovarian Cancer; http:\/\/eco.iarc.fr\/EUCAN\/CancerOne.aspx?Cancer=27&Gender=2 (November 2013, date last accessed)"},{"issue":"4","key":"10.1093\/annonc\/mdu392_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"17","key":"10.1093\/annonc\/mdu392_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdu392_bb0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu392_bb0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2002.20.4.1147","article-title":"Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide","volume":"20","author":"Abramson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdu392_bb0035","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ygyno.2006.05.035","article-title":"Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma","volume":"103","author":"Chan","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jpm.2006.0083","article-title":"Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer","volume":"10","author":"Gordinier","year":"2007","journal-title":"J Palliat Med"},{"issue":"3","key":"10.1093\/annonc\/mdu392_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0050","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1208\/aapsj070103","article-title":"Properties of thalidomide and its analogues: implications for anticancer therapy","volume":"7","author":"Teo","year":"2005","journal-title":"AAPS J"},{"issue":"7","key":"10.1093\/annonc\/mdu392_bb0055","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mdu392_bb0060","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00280-012-1874-2","article-title":"Lenalidomide in solid tumors","volume":"69","author":"Segler","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"10.1093\/annonc\/mdu392_bb0065","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ejca.2006.05.018","article-title":"Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies","volume":"42","author":"Sharma","year":"2006","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2006.11.026","article-title":"Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma","volume":"105","author":"Zhang","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu392_bb0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CGC.2004.n.006","article-title":"A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer","volume":"2","author":"Tohnya","year":"2004","journal-title":"Clin Prostate Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdu392_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdu392_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2008.06.028","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer","volume":"111","author":"Ghamande","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu392_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma","volume":"128","author":"Campos","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1093\/annonc\/mdu392_bb0105","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9747","key":"10.1093\/annonc\/mdu392_bb0110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdu392_bb0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3802\/jgo.2013.24.1.52","article-title":"Effect of ovarian tumor characteristics on venous thromboembolic risk","volume":"24","author":"Bakhru","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu392_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.23164","article-title":"A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma","volume":"112","author":"Downs","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdu392_bb0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10147-011-0243-1","article-title":"A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma","volume":"16","author":"Carter","year":"2011","journal-title":"Int J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/11\/2191\/326147\/mdu392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:32:19Z","timestamp":1624519939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0923753419367791"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu392","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}